Navigation Links
Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
Date:11/12/2012

mic antibiotics is the development of CDI, which may alter the balance of the GI microflora that normally protect the GI tract from C. diff overgrowth and infection. Other risk factors for CDI include hospitalization, prolonged length of stay, underlying illness, immune-compromising conditions including the administration of chemotherapy, and advanced age.

CDI is a widespread and often drug resistant infectious disease, resulting in more than 337,000 hospitalizations and 30,000 deaths in the U.S. during 2009.[3] CDI has surpassed methicillin-resistant staphylococcus aureus (MRSA) as the most frequent infection acquired in the hospital. It has recently been reported by The Centers for Disease Control and Prevention that the current number of CDI cases may be as high as 500,000 annually in the U.S. Controlling the spread of CDI has proven challenging, as the C. diff spores are easily transferred to patients via the hands of healthcare personnel. There is currently no vaccine or approved product for the prevention of C. diff infection.

Synthetic Biologics' Product Candidate: SYN-004

The acquisition includes the clinical-stage and related beta-lactamase assets, P1A, P2A and P3A (now known as SYN-004). Phase I studies of P1A, the first compound in the series, showed acceptable safety and tolerability. In addition, two Phase II clinical studies demonstrated its ability to preserve GI microflora in hospitalized patients treated with intravenous ampicillin or the combination of piperacillin and tazobactam.

SYN-004 has a broader spectrum of activity against beta-lactam antibiotics, including both penicillins and most cephalosporins. Due to the structural similarities between P1A and SYN-004, and based on previous discussions with the FDA, it is anticipated that the preclinical and manufacturing data collected on P1A may be used in support of an IND for Synthetic Biologics' new product candidate, SYN-004, for the prevent
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Taming mavericks: Stanford researchers use synthetic magnetism to control light
2. Synthetic Biologics Completes $10.8 Million Private Placement Financing
3. Synthetic Biologics Announces $10.8 Million Financing
4. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
5. Synthetic Biology Market is Expected to Reach USD 16.7 Billion Globally in 2018: Transparency Market Research
6. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
7. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
8. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
9. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
10. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
11. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... WIEN , July 3, 2015 /PRNewswire/ ... indtil den 22. september 2015 på  http://www.openinnovationinscience.at ... in Science", der finder sted i ... en nylig undersøgelse af internationale forskere og ... er de to største udfordringer for sundhedsvidenskaben ...
(Date:7/2/2015)... 2015 College of DuPage students Sam ... invaluable real-world experiences while serving biophysics internships at the ... The students will be working as a part of ... at IIT. The internship came about from a discussion ... Dr. Kathy Finan , Biology; and Dr. Wereszczynski ...
(Date:7/2/2015)... GLASGOW, Scotland , July 2, 2015 ...   Bio-tech procurement company Amici Procurement has ... IOM) to help it move to Office 365. ... Procurement provides small to medium-sized companies in the ... with all aspects of the purchasing cycle to help ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... development and manufacturing of surgical instruments in Orthopedics, announced today the acquisition of ... and the world's largest provider of surgical instruments to the Spine Industry. The ...
Breaking Biology Technology:Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3COD Students Participate in Prestigious Summer Internships 2Biotech Procurement Company Moves to Office 365 with iomart 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3
... is the first complement inhibitor to be tested ... Potentia Pharmaceuticals, a,privately held biotechnology company developing ... announced today that the Company,will be presenting its ... drug,candidate, POT-4, during the Retina Subspecialty Day at ...
... Oral Contraceptive,for the Prevention of Pregnancy, ... (NYSE: BRL ) today announced that ... approved its subsidiary Duramed Pharmaceuticals, Inc.,s New ... mg/0.02 mg and ethinyl estradiol tablets 0.01 ...
... Initiates Rosetta Green, a Project Which Will Leverage Rosetta Genomics, Proprietary microRNA Technologies and Strong IP ... Range of Plant-Based Applications, The Company has Recently Secured ... Trenches as Certain Milestones are ... Reached, Rosetta has Already Identified microRNAs Correlated With Algal Oil Content ...
Cached Biology Technology:Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting 2Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting 3FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 2FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 3FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 4FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 5Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 2Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 3Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 4
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:6/25/2015)... 25, 2015 According to ... (Swipe & Area), Technology, Material (Optical Prism, Piezoelectric, ... Security & Others) & Geography - Global Forecast ... said market is expected to reach $14,500.07 Million ... Browse 76 market Tables and 109 ...
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... requires activation of a molecule on the surface of B ... uses in its insidious attack on the immune system, University ... Conference (AIDS 2006). , "The research supports a new role ... between cells, with important implications for future studies and drug ...
... Health today provided the clearest picture yet of the prevalence ... with an increased risk of breast cancer. The genes are ... In addition, the study identified key predictors for assessing which ... , Each year, approximately 200,000 women in the United States ...
... with a rare disease in which patients develop multiple, benign ... found throughout the body, according to a report in the ... results from the loss of a gene called CYLD, causing ... studies indicated a role for CYLD in inflammation, but the ...
Cached Biology News:HIV infection requires an accomplice: B cells with special protein direct HIV to T cells 2New findings offer more complete view of breast cancer gene mutations in US population 2New findings offer more complete view of breast cancer gene mutations in US population 3Gene first linked to rare disease may trigger skin cancer, other tumors 2Gene first linked to rare disease may trigger skin cancer, other tumors 3
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
... an expertise in the forefront of chemical ... synthesis and synthesis in solution. , Our ... and analytical HPLC at no extra cost, ... the highest quality standard. , Our team ...
... The new Thermo Electron RapidStak provides ... tasks. Utilizing a unique buffer nest technology ... loading, the RapidStak provides fast, reliable automation ... productivity and walk-away confidence. The RapidStak can ...
Recombinant Rhesus Monkey IFN Alpha Activity: 2.9 x 10 8 u/mg...
Biology Products: